迁移侵袭抑制蛋白在肿瘤发生发展中的作用及其临床意义

The role and clinical significance of migration and invasion inhibitory protein in the development and progression of tumors

迁移侵袭抑制蛋白(migration and invasion inhibitory protein,MIIP)能够与胰岛素样生长因子结合蛋白2(insulin-like growth factor binding protein 2,IGFBP2)、组蛋白去乙酰化酶6(histone deacetylase 6,HDAC6)、p21活化激酶1、表皮生长因子受体、细胞分裂周期20(cell division cycle 20,cdc20)、拓扑异构酶等相互作用,抑制细胞增殖和迁移侵袭,进而抑制多种肿瘤的发生发展。最近的研究显示,MIIP还与病毒感染、细胞免疫有关。鉴于MIIP的作用涉及到多条肿瘤相关的信号通路及肿瘤治疗靶点,MIIP逐渐成为研究的热点。本文主要围绕MIIP的分子特征、功能和在多种肿瘤中的临床意义及作用机制进行综述。

Migration and invasion inhibitory protein （MIIP） inhibits cell proliferation, migration, and invasion, impeding tumorigenesis and tumor progression, by interacting with insulin-like growth factor binding protein 2 （IGFBP2）, histone deacetylase 6 （HDAC6）, p21 activated kinase i （PAK1）, epidermal growth factor receptor （EGFR）, cell division cycle 20 （CDC20）, and topoisomerase. Recent studies revealed potential roles of MIIP in viral infection and cellular immunity. MIIP has become a research hotspot owing to its involvement in multiple signaling pathways and as a potential therapeutic target for tumors. This review summarizes the characteristics, functions, clinical significance, and possible pathogenic mechanisms of MIIP in multiple carcinomas.